$0.82
arrow_drop_down2.70%Key Stats | |
---|---|
Open | $0.87 |
Prev. Close | $0.85 |
EPS | -0.72 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $8.67M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.77 | 0.87 |
52 Week Range | 0.25 | 4.05 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.72 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Nexalin Technology Announces Closing of $5.2 Million Public Offering
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts